Cerebrolysin
Cerebrolysin (FPE 1070)
A mixture of neuropeptides and amino acids derived from porcine brain tissue. Approved in many countries for stroke, traumatic brain injury, and Alzheimer's disease treatment.
Mechanism of Action
Cerebrolysin contains multiple neurotrophic factors that mimic the actions of BDNF, NGF, and CNTF. It promotes neuronal survival, neuroplasticity, and synaptic function while reducing neuroinflammation and oxidative stress.
Health Claims & Evidence
Neuroprotection and cognitive enhancement
Improves outcomes after stroke and TBI
Slows Alzheimer's disease progression
Enhances neuroplasticity and learning
Short-Term Effects
Improved focus, memory, and mood within days of starting a course.
Long-Term Effects
Sustained cognitive improvements, neuroprotection, and potential disease modification.
Side Effects
Generally well-tolerated. Mild dizziness, agitation, or sleep disturbance. Rare allergic reactions.
Contraindications
Avoid with epilepsy. Use with caution in renal impairment.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
Cerebrolysin in acute ischemic stroke
Ladurner et al. · Journal of Neural Transmission · 2005
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on Cerebrolysin and related peptides, and prepare an educational research summary.
Explore Research